Equally, it is not generally possible to achieve the same level of medical care by screeiing and nonscreening methods. The whole point of screening in some cases is that it is thought to be possible to achieve better results after early diagnosis than can be achieved later by any means.
The arguments in favour of profile screening, and particularly in favour of admission profiles, are largely concerned with length of stay. Although shortening stay leads to a reduction in costs per case, it implies an increase in the average intensity of care, and may result in a rise in costs per occupied bed per day.
The law of diminishing returns probably applies to the number of tests performed in terms of the quality of diagnosis achieved. Revenue costs may be low, but the question is how many channels are justified for routine purposes. A distinction should be maintained between tests which are diagnostic in intention and those which aim at case-finding. The implications of casefinding for medical costs and priorities are much greater than those of diagnosis.
Screening by its nature cannot be cheap, but its cost can be reduced somewhat by limiting the population to which it is applied. It must be recognized, however, that there is never an absolute cut-off in terms of specific prevalence and an economic judgment is always involved. One cuts down the cost but one misses some cases. The right cut-off level is where the extra cases missed are just about not worth the money saved. As in so many areas of social policy there is some danger that resources will get diverted into services which are characteristically taken up by the less needy.
Cost information is scarce, but a reasonable estimate for an effective automated multiple screening programme up to first-stage referral might be £100-200m per annum. It is unlikely that one could find economies in other forms of case-finding and referral on an equivalent scale, so that there would be an inevitable switch of resources from treatment to case-finding. Simultaneously there would be an increased demand for treatment from the new cases found, so that the average amount of treatment resources available per case would be further reduced. The case has not been made for a switch on this scale.
Screening as case-finding involves a significant switch, not simply between techniques, but between priorities. Thorough-going screening programmes for both breast cancer and cancer of the cervix would cost about as much as, and possibly more than, the present total cost to the health service of treating these conditions. In the early years, at least until the preventive measures began to take effect, the resources devoted to these diseases might well be more than doubled, because of the costs of the early treatment, sacrificing services in perhaps quite different areas ofhealth care.
The extent to which the advantages of industrialized techniques can be claimed varies considerably among screenable conditions. The expensive screening tests are those which use a lot of labour, such as the cancer programmes. How far is it sensible to switch resources between testsfrom physical examination to biochemical testingwhen the conditions screened for may be quite different ?
The answer lies in effectiveness; in particular, the effectiveness of treatment. Unfortunately there seems to be no settled opinion among doctors on the effectiveness of several forms of screening. Medical evaluation has to precede economic evaluation.
Dr M HB Carmalt and Professor T P Whitehead (Queen Elizabeth Hospital, Birmingham, B15 2TH)
Patient Investigation by Biochemical Profile
Biochemical profile is a group of tests performed irrespective of diagnosis on all patients in a given situation. Advances in automation have made profiles possible; however, it is important to know the effects on patient care. Since 1967, at the Queen Elizabeth Hospital, Birmingham, biochemical profiles have been performed on patients in the wards and in the outpatients' department and on those attending in general practice (Whitehead et al. 1967 , Whitehead 1968 , Carmalt 1969 , Whitehead & Carmalt 1969 , Carmalt et al. 1970 . From each patient 20 ml of blood is taken and fourteen to sixteen biochemical results obtained on the day of arrival of each specimen. The profile tests include those most commonly requested, tests which form part of a grouped analysis and others which are truly screening tests (Table 1) . Table 2 shows the results of a questionnaire completed on every patient by the clinician. In the hospital patients this was completed two weeks after biochemical analysis, but in the general practice cases completion was delayed for three months. This delay partly accounts for the different percentages found in general practice, although these profiles also included htematology.
Over 77% of the profile tests would not have been requested. As a result of unrequested tests 6-8 3 % of hospital patients had a new or additional diagnosis of varying clinical significance. Of 92 randomly chosen inpatients with diagnostic results, over half had a diagnosis of diabetes mellitus or iron deficiency anemia; in 30 of these the profile had altered the form of management.
An important finding resulting from the unrequested tests is the high percentage of patients with unexpected abnormal results. There are at least four reasons for this:
(1) Variation with sex and age: Surveys on the normal population have shown changes in many biochemical parameters associated with sex or age. Such analysis of the urea results in the profile patients yields very similar changes to those found by Campbell et al. (1968) in the normal Welsh population. A proportion of the unexplained results can be accounted for if adequate allowance is made for such changes.
(2) Laboratory error: Abnormalities may arise from the techniques used in blood collection, specimen handling and analysis. Two teststotal carbon dioxide and zinc sulphate turbiditywere dropped from the profile because of difficulties in analysis as well as low yield of information.
(3) Unknown effects of disease or drugs: Since profiles are performed on all patients, some changes resulting from disease or drugs may be unknown or the clinician may be unaware of them. Thus not all clinicians were aware of the low serum iron in inflammatory states (Cartwright & Wintrobe 1949) .
(4) Undiagnosed disease present: This may be either presymptomatic, or symptomatic and diagnostically difficult. Thus serum calcium has resulted in the diagnosis of malabsorption syndrome or hyperparathyroidism, unsuspected on clinical grounds. Unsuspected drug reactions have been found. A review of the notes of a group of inpatients with unexplained results has shown that after one year the percentage of these falls from 36-1 % to 15-5% (Carmalt 1969) . Many results were not followed up; some of these could represent presymptomatic disease. In 124% of patients the results were accounted for by subsequent clinical findings or knowledge about the biochemical changes due to disease or age. In 4.3 % of patients, the results were explained on technical grounds. However, in 3 9 % of patients, results initially unexplained were of clinical importance.
Normal results are also of value. They exclude certain disease, act as a base line for future disorders and may help to assess the fitness of a patient for certain treatment. They also help in the interpretation of abnormal results.
No detectable change in bed stay has been observed in those wards where the profile scheme has been introduced compared with other wards. Where patients under three physicians were randomly allocated to a profile or control group, the only difference in bed stay was a reduction in patients of the profile group admitted under one physician (Table 3) .
Costing of the present scheme and that of Bryan et al. (1966) has shown that the cost of full profile is equal to that of two to three tests requested routinely.
Further work is now needed to determine which group of patients benefits most from biochemical profiles and whether the most appropriate time is at outpatients, on the ward or in the GP's surgery. A profile's value depends both on the production of reliable results by the laboratory and on the use of the information by the clinician.
Dr M Levene (Cytopathology Unit, St Helier Hospital, Carshalton, Surrey)
The Development ofa Metropolitan Regional Cytology Service Clinical cytological examination is concerned at present mainly with cancer, particularly cervical cancer. From correlation of cytological studies with careful histological evaluation of biopsies three groups of epithelial disorder have emerged: invasive carcinoma, carcinoma-in-situ and dysplasias. Large-scale use of smear examinations has revealed numerous examples of dysplasias in younger women. The view has developed that, over an unknown period of time, a series of changes may occur in cervical epithelium and that invasive carcinoma may result from the progression of dysplasia to carcinoma-in-situ to invasion. The logical assumption was that if early lesions could be discovered and excised locally, the incidence of invasive carcinoma would be reduced.
Many people believe that this hypothesis is not proven and that the expense is not justified. This paper attempts to answer the question: 'To what degree was there justification for the provision of such regionalized laboratory facilities as ours? ' A service was initially developed in 1965 for the consultant gynmcologists to whom problem cases would be referred, an expected figure being about 20 in every 1,000. Today, the laboratory deals with up to 4,000 cases per month from hospital, local health authorities, general practitioners and family planning clinics, as well as providing other cytodiagnostic facilities. It was desirable to acquire information which would shed light on the natural history of cervical cancer, and possibly also uterus and breast cancer. Careful record design and the development of a computerized retrieval and information system are making this feasible.
Various factors are beyond the control of the laboratory, such as the content and quality of the cervical smear. This consists of a heterogeneous collection of epithelial and mesenchymal cells in various stages of viability. The sample may not be easily repeatable and we regard the cell population as a mirror of physiological and pathological processes, the latter reflecting inflammation or neoplasia. In reporting, we use a modified Papanicolaou classification, whose primary purpose is to standardize communication within the laboratory, and we add any comment which may help in clinical management. We emphasize that our role is to aid diagnosis and not to act as a diagnostic slot machine. Some cytologists claim high diagnostic accuracy in predicting a tumour diagnosis from the cytological picture; we do this as an exercise only, and will only know with what accuracy when we review our material. We have tried to develop a policy of two smears within the first year, so as to reduce error, and a third within five years. A suitable analogy is that of a driver going through a series of traffic signals, say about ten in a lifetime. If the signals are green (Class I, II) all is well. There may be an amber (Class III) which can revert to green, but red (Class IV, V) means stop: 'Go and see a competent gynecologist'.
Our analysed data illustrate some of the variables. In June 1966, we participated in a tenday health screening exercise at Epsom. One consultant gynecologist analysed 1,200 cases examined by his team. He found that 1 woman in 7 had an erosion; 1 in 36 a cervicitis (cysts, scars or discharge); 1 in 25 a polyp; 1 in 57 fibroids; and 1 in 171 an ovarian or adnexal mass. This is a
